{"title":"斯里兰卡食管癌和胃癌患者的预后:回顾性生存分析。","authors":"Sidath Wijesekera, Lanka Alagiyawanna, Vimukthini Peiris, Damitha Chathuranga Silva, Tiromi Rupasinghe, Jayantha Balawardena, Thurairajah Skandarajah, Nadarajah Jeyakumaran, Dehan Gunasekera, Minoli Bandusena, Nuradh Joseph","doi":"10.4103/jcrt.jcrt_817_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Esophageal carcinoma is the fourth most common cancer among males and sixth most common cancer among females in Sri Lanka. Gastric cancer is less common, but its incidence is gradually rising. We conducted a retrospective analysis of survival of esophageal and gastric cancer patients treated at National Cancer Institute, Maharagama, Sri Lanka.</p><p><strong>Methodology: </strong>Patients with esophageal and gastric cancer treated in three selected oncology units of the National Cancer Institute, Maharagama during 2015 and 2016 were included in the study. Data on clinical and pathological factors were extracted from clinical records. Overall survival (OS), defined as time to death or loss to follow-up, was the primary endpoint. Univariate and multivariate analyses of survival were performed using the log-rank test and Cox proportional-hazard model, respectively.</p><p><strong>Results: </strong>The study population comprised 374 patients with a median age of 62 years (interquartile range 55-70). Majority (64%) were male and had squamous cell carcinoma (58%). In the sample, 20% were gastric cancers, while 71% were esophageal cancers, and 9% had gastro-esophageal junction tumors. The 2-year OS was 19% in patients treated with curative intent (95% confidence interval [CI] 14-26 months) with those receiving neoadjuvant chemotherapy, followed by radical surgery having the highest survival (P < 0.001, hazard ratio 0.25 [95% CI 0.11-0.56]). Median OS was 2 months (95% CI 1-2 months) in patients treated with palliative intent.</p><p><strong>Conclusion: </strong>Our results suggest that the outcome of patients with esophageal and gastric cancer is poor in Sri Lanka. Early detection and greater utilization of multimodality treatment could improve outcomes of these patients.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of patients with esophageal and gastric cancer in Sri Lanka: A retrospective survival analysis.\",\"authors\":\"Sidath Wijesekera, Lanka Alagiyawanna, Vimukthini Peiris, Damitha Chathuranga Silva, Tiromi Rupasinghe, Jayantha Balawardena, Thurairajah Skandarajah, Nadarajah Jeyakumaran, Dehan Gunasekera, Minoli Bandusena, Nuradh Joseph\",\"doi\":\"10.4103/jcrt.jcrt_817_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Esophageal carcinoma is the fourth most common cancer among males and sixth most common cancer among females in Sri Lanka. Gastric cancer is less common, but its incidence is gradually rising. We conducted a retrospective analysis of survival of esophageal and gastric cancer patients treated at National Cancer Institute, Maharagama, Sri Lanka.</p><p><strong>Methodology: </strong>Patients with esophageal and gastric cancer treated in three selected oncology units of the National Cancer Institute, Maharagama during 2015 and 2016 were included in the study. Data on clinical and pathological factors were extracted from clinical records. Overall survival (OS), defined as time to death or loss to follow-up, was the primary endpoint. Univariate and multivariate analyses of survival were performed using the log-rank test and Cox proportional-hazard model, respectively.</p><p><strong>Results: </strong>The study population comprised 374 patients with a median age of 62 years (interquartile range 55-70). Majority (64%) were male and had squamous cell carcinoma (58%). In the sample, 20% were gastric cancers, while 71% were esophageal cancers, and 9% had gastro-esophageal junction tumors. The 2-year OS was 19% in patients treated with curative intent (95% confidence interval [CI] 14-26 months) with those receiving neoadjuvant chemotherapy, followed by radical surgery having the highest survival (P < 0.001, hazard ratio 0.25 [95% CI 0.11-0.56]). Median OS was 2 months (95% CI 1-2 months) in patients treated with palliative intent.</p><p><strong>Conclusion: </strong>Our results suggest that the outcome of patients with esophageal and gastric cancer is poor in Sri Lanka. Early detection and greater utilization of multimodality treatment could improve outcomes of these patients.</p>\",\"PeriodicalId\":15208,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_817_21\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_817_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
食管癌是斯里兰卡男性中第四大最常见的癌症,女性中第六大最常见的癌症。胃癌虽不常见,但发病率正逐渐上升。我们对在斯里兰卡Maharagama国立癌症研究所治疗的食管癌和胃癌患者的生存率进行了回顾性分析。方法:选取2015年至2016年在Maharagama国立癌症研究所三个肿瘤单位接受治疗的食管癌和胃癌患者纳入研究。从临床记录中提取临床和病理因素数据。总生存期(OS),定义为死亡时间或随访损失,是主要终点。生存率的单因素和多因素分析分别采用log-rank检验和Cox比例风险模型。结果:研究人群包括374例患者,中位年龄为62岁(四分位数范围为55-70)。大多数(64%)为男性,并患有鳞状细胞癌(58%)。在样本中,20%为胃癌,71%为食管癌,9%为胃-食管交界处肿瘤。以治愈为目的治疗的患者2年OS为19%(95%可信区间[CI] 14-26个月),其中接受新辅助化疗的患者生存率最高(P < 0.001,风险比为0.25 [95% CI 0.11-0.56])。以姑息治疗为目的的患者中位OS为2个月(95% CI为1-2个月)。结论:我们的研究结果表明,斯里兰卡食管癌和胃癌患者的预后较差。早期发现和更多地利用多模式治疗可以改善这些患者的预后。
Outcomes of patients with esophageal and gastric cancer in Sri Lanka: A retrospective survival analysis.
Introduction: Esophageal carcinoma is the fourth most common cancer among males and sixth most common cancer among females in Sri Lanka. Gastric cancer is less common, but its incidence is gradually rising. We conducted a retrospective analysis of survival of esophageal and gastric cancer patients treated at National Cancer Institute, Maharagama, Sri Lanka.
Methodology: Patients with esophageal and gastric cancer treated in three selected oncology units of the National Cancer Institute, Maharagama during 2015 and 2016 were included in the study. Data on clinical and pathological factors were extracted from clinical records. Overall survival (OS), defined as time to death or loss to follow-up, was the primary endpoint. Univariate and multivariate analyses of survival were performed using the log-rank test and Cox proportional-hazard model, respectively.
Results: The study population comprised 374 patients with a median age of 62 years (interquartile range 55-70). Majority (64%) were male and had squamous cell carcinoma (58%). In the sample, 20% were gastric cancers, while 71% were esophageal cancers, and 9% had gastro-esophageal junction tumors. The 2-year OS was 19% in patients treated with curative intent (95% confidence interval [CI] 14-26 months) with those receiving neoadjuvant chemotherapy, followed by radical surgery having the highest survival (P < 0.001, hazard ratio 0.25 [95% CI 0.11-0.56]). Median OS was 2 months (95% CI 1-2 months) in patients treated with palliative intent.
Conclusion: Our results suggest that the outcome of patients with esophageal and gastric cancer is poor in Sri Lanka. Early detection and greater utilization of multimodality treatment could improve outcomes of these patients.
期刊介绍:
The journal will cover technical and clinical studies related to health, ethical and social issues in field of Medical oncology, radiation oncology, medical imaging, radiation protection, non-ionising radiation, radiobiology. Articles with clinical interest and implications will be given preference.